Bactiguard Holding AB (CHIX:BACTBS) Research & Development: kr0.0 Mil (TTM As of Mar. 2026)


CHIX:BACTBS Bactiguard Holding AB CHIX:BACTBS
48 GF Score
Price kr128.60
GF Value kr264.39
! 3 Warning Signs
View Full Analysis

What is Bactiguard Holding AB Research & Development?

Bactiguard Holding AB CHIX:BACTBS 48 Research & Development is kr0.0 Mil as of Mar. 2026. GuruFocus rates CHIX:BACTBS with a GF Score™ of 48/100 and a GF Value™ of kr264.39. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Bactiguard Holding AB's Research & Development for the three months ended in Mar. 2026 was kr0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.0 Mil.

Bactiguard Holding AB  (CHIX:BACTBs) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Bactiguard Holding AB Research & Development Related Terms

Bactiguard Holding AB Research & Development Historical Data

* Premium members only.

The historical data trend for Bactiguard Holding AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bactiguard Holding AB Research & Development Chart

Bactiguard Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bactiguard Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:BACTBS
48GF Score
Bactiguard Holding AB CHIX:BACTBS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bactiguard Holding AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of kr0.0 Mil mean?
Bactiguard Holding AB (CHIX:BACTBS) has a Research & Development of kr0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Bactiguard Holding AB and its competitors.
Is Bactiguard Holding AB's Research & Development too high?
Bactiguard Holding AB's current Research & Development is kr0.0 Mil. Overall, Bactiguard Holding AB has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Bactiguard Holding AB's Research & Development compare to ABT and SYK?
Bactiguard Holding AB's Research & Development of kr0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Bactiguard Holding AB and its competitors. Bactiguard Holding AB's current Research & Development is kr0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bactiguard Holding AB stock overvalued right now?
Bactiguard Holding AB (CHIX:BACTBS) has a current Research & Development of kr0.0 Mil. The stock's GF Value™ is kr264.39, compared to a current price of kr128.60 — trading 51.4% below its estimated fair value. The current Research & Development is kr0.0 Mil. Bactiguard Holding AB's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Bactiguard Holding AB (CHIX:BACTBS), the current Research & Development is kr0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bactiguard Holding AB (CHIX:BACTBS) Overvalued in 2026?

Based on GuruFocus' analysis, Bactiguard Holding AB stock appears to be undervalued. The current stock price of kr128.60 is trading 51.4% below its estimated GF Value™ of kr264.39.

Key valuation signals for CHIX:BACTBS:

  • Research & Development: kr0.0 Mil
  • GF Value™: kr264.39 vs. price of kr128.60 (51.4% below fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the CHIX:BACTBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bactiguard Holding AB Business Description

Other Exchanges BACTI B:Sweden5JE:Germany
Address Vasagatan 11, Stockholm, SWE, 111 20
Bactiguard Holding AB is a medical device company. It is engaged in a MedTech company developing safe and biocompatible technology to prevent medical device-related infections. The technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas wherein infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access. Geographically, the company operates in the USA, Malaysia, China, Saudi Arabia, Bangladesh, Sweden, the Czech Republic, and Other countries. The majority of its revenue is generated from the USA region.
48GF Score

Get the complete analysis for CHIX:BACTBS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr128.60
Price
kr264.39
GF Value